{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:20:46Z","timestamp":1780316446641,"version":"3.54.1"},"reference-count":35,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      The aim of the present study was to examine the clinical distribution and antibiotic susceptibility of the\n                      <jats:italic toggle=\"yes\">Burkholderia cepacia<\/jats:italic>\n                      complex (BCC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The BCC clinical strains were obtained from the First Affiliated Hospital of Zhejiang University School of Medicine in China from January 2019 to January 2024, and\n                      <jats:italic toggle=\"yes\">hisA<\/jats:italic>\n                      gene sequencing was employed for strain identification. The\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      susceptibility of various antibacterials was measured through the disk diffusion method and the broth microdilution method.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 386 strains of BCC were collected. Among them, the most common strains were\n                      <jats:italic toggle=\"yes\">B. cenocepacia<\/jats:italic>\n                      (45.9%),\n                      <jats:italic toggle=\"yes\">B. multivorans<\/jats:italic>\n                      (45.1%), and\n                      <jats:italic toggle=\"yes\">B. contaminans<\/jats:italic>\n                      (7.0%).\n                      <jats:italic toggle=\"yes\">B. multivorans<\/jats:italic>\n                      was the main one in respiratory specimens, whereas\n                      <jats:italic toggle=\"yes\">B. cenocepacia<\/jats:italic>\n                      dominated in blood specimens.\n                      <jats:italic toggle=\"yes\">B. cenocepacia<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">B. multivorans<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">B. contaminans<\/jats:italic>\n                      exhibited a susceptibility over 95% to meropenem and sulfamethoxazole\u2013trimethoprim, whereas varying sensitivities were displayed to levofloxacin, ceftazidime, and minocycline (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.05). Among tetracyclines, eravacycline exhibited the lowest minimum inhibitory concentration 90 (MIC90) values 1 \u00b5g\/mL for\n                      <jats:italic toggle=\"yes\">B. cenocepacia<\/jats:italic>\n                      , 1 \u00b5g\/mL for\n                      <jats:italic toggle=\"yes\">B. multivorans<\/jats:italic>\n                      , and 2 \u00b5g\/mL for\n                      <jats:italic toggle=\"yes\">B. contaminans<\/jats:italic>\n                      . This was followed by tigecycline (MIC90: 2 \u00b5g\/mL, 2 \u00b5g\/mL, and 4 \u00b5g\/mL, respectively), minocycline (MIC90: 8 \u00b5g\/mL, 2 \u00b5g\/mL, and 8 \u00b5g\/mL, respectively), and omadacycline (MIC90: 8 \u00b5g\/mL, 4 \u00b5g\/mL, and 16 \u00b5g\/mL, respectively). Compared with the broth microdilution method, the category agreement (CA) of sulfamethoxazole\u2013trimethoprim and ceftazidime was &gt;95%, and the very major error was &lt;1%, whereas the CA of minocycline and meropenem was &lt;90%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Thus, there are differences in the\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      antimicrobial susceptibility of different BCC strains, with eravacycline demonstrating lower MIC values compared with tigecycline, minocycline, and omadacycline.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/mdr.2024.0220","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:59:37Z","timestamp":1745413177000},"page":"154-161","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Species Distribution and Antimicrobial Susceptibility of Diverse Strains Within\n                    <i>Burkholderia cepacia<\/i>\n                    Complex"],"prefix":"10.1177","volume":"31","author":[{"given":"Ke","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratories, The Second Hospital of Yinzhou, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiong","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratories, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxi","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratories, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratories, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengchao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratories, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratories, The Second Hospital of Yinzhou, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratories, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"1","key":"e_1_3_5_2_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13062-020-0258-5","article-title":"Genome-based classification of Burkholderia cepacia complex provides new insight into its taxonomic status","volume":"15","author":"Jin Y","year":"2020","unstructured":"Jin Y, , Zhou JL, , Zhou J, et al. Genome-based classification of Burkholderia cepacia complex provides new insight into its taxonomic status. Biol Direct, 2020; 15(1):6; doi: 10.1186\/s13062-020-0258-5","journal-title":"Biol Direct"},{"issue":"7","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1469-0691.2010.03237.x","article-title":"Burkholderia cenocepacia in cystic fibrosis: Epidemiology and molecular mechanisms of virulence","volume":"16","author":"Drevinek P","year":"2010","unstructured":"Drevinek P, , Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: Epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect, 2010; 16(7):821\u2013830; doi: 10.1111\/j.1469-0691.2010.03237.x","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ppul.26359","article-title":"Cepacia syndrome in cystic fibrosis: A systematic review of the literature and possible new perspectives in treatment","volume":"58","author":"Dacco V","year":"2023","unstructured":"Dacco V, , Alicandro G, , Consales A, et al. Cepacia syndrome in cystic fibrosis: A systematic review of the literature and possible new perspectives in treatment. Pediatr Pulmonol, 2023; 58(5):1337\u20131343; doi: 10.1002\/ppul.26359","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1099\/jmm.0.019844-0","article-title":"Identification of species of the Burkholderia cepacia complex by sequence analysis of the hisA gene","volume":"59","author":"Papaleo MC","year":"2010","unstructured":"Papaleo MC, , Perrin E, , Maida I, et al. Identification of species of the Burkholderia cepacia complex by sequence analysis of the hisA gene. J Med Microbiol, 2010; 59(Pt 10):1163\u20131170; doi: 10.1099\/jmm.0.019844-0","journal-title":"J Med Microbiol"},{"issue":"1","key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12941-019-0306-0","article-title":"Accurate identification and epidemiological characterization of Burkholderia cepacia complex: An update","volume":"18","author":"Devanga Ragupathi NK","year":"2019","unstructured":"Devanga Ragupathi NK, , Veeraraghavan B. Accurate identification and epidemiological characterization of Burkholderia cepacia complex: An update. Ann Clin Microbiol Antimicrob, 2019; 18(1):7; doi: 10.1186\/s12941-019-0306-0","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"e_1_3_5_7_2","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100","year":"2023","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100. 33rd ed. CLSI: Wayne, PA; 2023.","edition":"33"},{"issue":"6","key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1128\/JCM.43.6.2926-2928.2005","article-title":"Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis","volume":"43","author":"Reik R","year":"2005","unstructured":"Reik R, , Spilker T, , Lipuma JJ. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol, 2005; 43(6):2926\u20132928; doi: 10.1128\/JCM.43.6.2926-2928.2005","journal-title":"J Clin Microbiol"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"1476041","DOI":"10.3389\/fmicb.2024.1476041","article-title":"Phage therapy to treat cystic fibrosis Burkholderia cepacia complex lung infections: Perspectives and challenges","volume":"15","author":"Canning JS","year":"2024","unstructured":"Canning JS, , Laucirica DR, , Ling K-M, , Nicol MP, , Stick SM, , Kicic A. Phage therapy to treat cystic fibrosis Burkholderia cepacia complex lung infections: Perspectives and challenges. Front Microbiol, 2024; 15:1476041; doi: 10.3389\/fmicb.2024.1476041","journal-title":"Front Microbiol"},{"issue":"2","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1128\/JB.00997-13","article-title":"Comparative metabolic systems analysis of pathogenic Burkholderia","volume":"196","author":"Bartell JA","year":"2014","unstructured":"Bartell JA, , Yen P, , Varga JJ, et al. Comparative metabolic systems analysis of pathogenic Burkholderia. J Bacteriol, 2014; 196(2):210\u2013226; doi: 10.1128\/JB.00997-13","journal-title":"J Bacteriol"},{"issue":"5","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"e0209821","DOI":"10.1128\/mBio.02098-21","article-title":"The Burkholderia cenocepacia type VI secretion system effector TecA is a virulence factor in mouse models of lung infection","volume":"12","author":"Loeven NA","year":"2021","unstructured":"Loeven NA, , Perault AI, , Cotter PA, et al. The Burkholderia cenocepacia type VI secretion system effector TecA is a virulence factor in mouse models of lung infection. mBio, 2021; 12(5):e0209821; doi: 10.1128\/mBio.02098-21","journal-title":"mBio"},{"issue":"2","key":"e_1_3_5_12_2","first-page":"717","article-title":"Molecular research comparing the probabilities of Burkholderia cepacia bacterium diagnosis procedures","volume":"77","author":"Maki Al-Nasrawy L","year":"2022","unstructured":"Maki Al-Nasrawy L, , Abdali SA, , Mohammed Jawad S. Molecular research comparing the probabilities of Burkholderia cepacia bacterium diagnosis procedures. Arch Razi Inst, 2022; 77(2):717\u2013725; doi: 10.22092\/ARI.2022.357464.2041","journal-title":"Arch Razi Inst"},{"issue":"1","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1513\/AnnalsATS.201408-395OC","article-title":"Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years\u2019 experience","volume":"12","author":"Zlosnik JEA","year":"2015","unstructured":"Zlosnik JEA, , Zhou G, , Brant R, et al. Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years\u2019 experience. Ann Am Thorac Soc, 2015; 12(1):70\u201378; doi: 10.1513\/AnnalsATS.201408-395OC","journal-title":"Ann Am Thorac Soc"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202003-204OC"},{"issue":"1","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"2307503","DOI":"10.1080\/07853890.2024.2307503","article-title":"Burkholderia cepacia complex in cystic fibrosis: Critical gaps in diagnosis and therapy","volume":"56","author":"Guti\u00e9rrez Santana JC","year":"2024","unstructured":"Guti\u00e9rrez Santana JC, , Coria Jim\u00e9nez VR. Burkholderia cepacia complex in cystic fibrosis: Critical gaps in diagnosis and therapy. Ann Med, 2024; 56(1):2307503; doi: 10.1080\/07853890.2024.2307503","journal-title":"Ann Med"},{"issue":"4","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00284-019-01653-4","article-title":"Whole genome sequence analysis of Burkholderia contaminans FFH2055 strain reveals the presence of putative \u03b2-Lactamases","volume":"76","author":"Degrossi JJ","year":"2019","unstructured":"Degrossi JJ, , Merino C, , Isasmendi AM, et al. Whole genome sequence analysis of Burkholderia contaminans FFH2055 strain reveals the presence of putative \u03b2-Lactamases. Curr Microbiol, 2019; 76(4):485\u2013494; doi: 10.1007\/s00284-019-01653-4","journal-title":"Curr Microbiol"},{"issue":"2","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cmi.2014.07.014","article-title":"Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis","volume":"21","author":"Medina-Pascual MJ","year":"2015","unstructured":"Medina-Pascual MJ, , Valdezate S, , Carrasco G, et al. Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect, 2015; 21(2):150\u2013156; doi: 10.1016\/j.cmi.2014.07.014","journal-title":"Clin Microbiol Infect"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jhin.2023.10.005","article-title":"Two consecutive outbreaks caused by chlorhexidine mouthwash contaminated with Burkholderia contaminans in a two-hospital tertiary care system","volume":"142","author":"Zunitan MA","year":"2023","unstructured":"Zunitan MA, , Aldawood F, , El-Saed A, et al. Two consecutive outbreaks caused by chlorhexidine mouthwash contaminated with Burkholderia contaminans in a two-hospital tertiary care system. J Hosp Infect, 2023; 142:96\u2013104; doi: 10.1016\/j.jhin.2023.10.005","journal-title":"J Hosp Infect"},{"issue":"8","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1017\/ice.2022.235","article-title":"An outbreak of Burkholderia contaminans at a quaternary children\u2019s hospital linked to equipment reprocessing","volume":"44","author":"Teoh Z","year":"2023","unstructured":"Teoh Z, , Ankrum AL, , Meinzen J, et al. An outbreak of Burkholderia contaminans at a quaternary children\u2019s hospital linked to equipment reprocessing. Infect Control Hosp Epidemiol, 2023; 44(8):1267\u20131273; doi: 10.1017\/ice.2022.235","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"e0160975","DOI":"10.1371\/journal.pone.0160975","article-title":"Understanding the pathogenicity of Burkholderia contaminans, an emerging pathogen in cystic fibrosis","volume":"11","author":"Nunvar J","year":"2016","unstructured":"Nunvar J, , Kalferstova L, , Bloodworth RA, et al. Understanding the pathogenicity of Burkholderia contaminans, an emerging pathogen in cystic fibrosis. PLoS One, 2016; 11(8):e0160975; doi: 10.1371\/journal.pone.0160975","journal-title":"PLoS One"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2016.07.003"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3389\/fmicb.2015.00668","article-title":"Potential of metabolomics to reveal Burkholderia cepacia complex pathogenesis and antibiotic resistance","volume":"6","author":"Shommu NS","year":"2015","unstructured":"Shommu NS, , Vogel HJ, , Storey DG. Potential of metabolomics to reveal Burkholderia cepacia complex pathogenesis and antibiotic resistance. Front Microbiol, 2015; 6:668; doi: 10.3389\/fmicb.2015.00668","journal-title":"Front Microbiol"},{"key":"e_1_3_5_23_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoints Tables and Intrinsic Resistance Guidelines. Version 15.0. Basel Switzerland: EUCAST; 2025. Includes: Intrinsic resistance tables and clinical breakpoints. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_15.0_Breakpoint_Tables.pdf [Last accessed: Mar20 2025]."},{"issue":"6","key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1099\/jmm.0.017830-0","article-title":"Approaches to measure the fitness of Burkholderia cepacia complex isolates","volume":"59","author":"Pope CF","year":"2010","unstructured":"Pope CF, , Gillespie SH, , Moore JE, et al. Approaches to measure the fitness of Burkholderia cepacia complex isolates. J Med Microbiol, 2010; 59(Pt 6):679\u2013686; doi: 10.1099\/jmm.0.017830-0","journal-title":"J Med Microbiol"},{"issue":"3","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1128\/AAC.00799-07","article-title":"Fluoroquinolone-resistant mutants of Burkholderia cepacia","volume":"52","author":"Pope CF","year":"2008","unstructured":"Pope CF, , Gillespie SH, , Pratten JR, et al. Fluoroquinolone-resistant mutants of Burkholderia cepacia. Antimicrob Agents Chemother, 2008; 52(3):1201\u20131203; doi: 10.1128\/AAC.00799-07","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1128\/AAC.01068-15","article-title":"Cell wall Recycling-Linked Coregulation of AmpC and PenB \u03b2-Lactamases through ampD mutations in Burkholderia cenocepacia","volume":"59","author":"Hwang J","year":"2015","unstructured":"Hwang J, , Kim HS. Cell wall Recycling-Linked Coregulation of AmpC and PenB \u03b2-Lactamases through ampD mutations in Burkholderia cenocepacia. Antimicrob Agents Chemother, 2015; 59(12):7602\u20137610; doi: 10.1128\/AAC.01068-15","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_27_2","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100[S]","author":"Clinical and Laboratory Standard Institute","year":"2025","unstructured":"Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100[S]. 35nd ed. CLSI: Wayne, PA; 2025.","edition":"35"},{"issue":"12","key":"e_1_3_5_28_2","first-page":"1429","article-title":"Molecular typing and drug susceptibility comparison of Burkholderia cepacia complex","volume":"22","author":"Zhou HW","year":"2013","unstructured":"Zhou HW, , Huang YL, , Yu H, et al. Molecular typing and drug susceptibility comparison of Burkholderia cepacia complex. Chin J Emergency Med, 2013; 22(12):1429\u20131429; doi: 10.3760\/cma.j.issn.1671-0282.2013.12.032","journal-title":"Chin J Emergency Med"},{"issue":"03","key":"e_1_3_5_29_2","article-title":"Clinical isolation and drug resistance monitoring of Burkholderia cepacia for 7 years","volume":"28","author":"Lu HX","year":"2005","unstructured":"Lu HX, , Shen BQ, , Hu QF, et al. Clinical isolation and drug resistance monitoring of Burkholderia cepacia for 7 years. Chin J Labor Med, 2005; 28(03); doi: 10.3760\/j:issn:1009-9158.2005.03.013","journal-title":"Chin J Labor Med"},{"issue":"2","key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1128\/AAC.43.2.213","article-title":"Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis","volume":"43","author":"Bonacorsi S","year":"1999","unstructured":"Bonacorsi S, , Fitoussi F, , Lhopital S, et al. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother, 1999; 43(2):213\u2013217; doi: 10.1128\/AAC.43.2.213","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In vitro activity of Eravacycline against Carbapenem-Resistant enterobacteriaceae and acinetobacter baumannii","volume":"60","author":"Livermore DM","year":"2016","unstructured":"Livermore DM, , Mushtaq S, , Warner M, et al. In vitro activity of Eravacycline against Carbapenem-Resistant enterobacteriaceae and acinetobacter baumannii. Antimicrob Agents Chemother, 2016; 60(6):3840\u20133844; doi: 10.1128\/AAC.00436-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-019-4093-1","article-title":"In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China","volume":"19","author":"Zhao C","year":"2019","unstructured":"Zhao C, , Wang X, , Zhang Y, et al. In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China. BMC Infect Dis, 2019; 19(1):508; doi: 10.1186\/s12879-019-4093-1","journal-title":"BMC Infect Dis"},{"issue":"3","key":"e_1_3_5_33_2","article-title":"In vitro activity of Eravacycline against Gram-Negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey I","year":"2020","unstructured":"Morrissey I, , Olesky M, , Hawser S, et al. In vitro activity of Eravacycline against Gram-Negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother, 2020; 64(3):e01699-19; doi: 10.1128\/AAC.01699-19","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2019.0423"},{"issue":"3","key":"e_1_3_5_35_2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01767-20","article-title":"Burkholderia ubonensis high-level tetracycline resistance is due to efflux pump synergy involving a novel TetA(64) resistance determinant","volume":"65","author":"Somprasong N","year":"2021","unstructured":"Somprasong N, , Hall CM, , Webb JR, et al. Burkholderia ubonensis high-level tetracycline resistance is due to efflux pump synergy involving a novel TetA(64) resistance determinant. Antimicrob Agents Chemother, 2021; 65(3):e01767-20; doi: 10.1128\/AAC.01767-20","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_36_2","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100[S]","author":"Clinical and Laboratory Standard Institute","year":"2024","unstructured":"Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100[S]. 34nd ed. CLSI: Wayne, PA; 2024.","edition":"34"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2024.0220","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:41:55Z","timestamp":1777668115000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2024.0220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1089\/mdr.2024.0220"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2024.0220","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}